Clinical Trials
22 trialsNCT05735717 2026-04-06
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT04395222 2026-01-06
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT07052370 2025-12-31
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT05579769 2025-10-02
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01810588 2025-09-02
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT01664910 2024-07-23
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT00185640 2021-06-29
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
Stanford University
Phase 2 Completed
NCT02129582 2021-05-07
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00506948 2020-09-24
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00439556 2019-09-10
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03818334 2019-02-01
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein
Phase 2/3 Recruiting
NCT01246206 2018-06-18
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01471067 2017-04-28
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01621477 2017-02-20
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00133367 2016-07-25
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital
Phase 2 Completed
NCT01056614 2016-05-06
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00720629 2014-07-18
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01622556 2014-02-11
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
University of Virginia
Phase 2 Terminated
NCT00795132 2013-07-30
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
University of Utah
Phase 2 Completed
NCT00750126 2011-01-19
RICE
University Hospital, Clermont-Ferrand
Phase 2 Unknown
NCT01217723 2010-10-08
Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
McMaster University
Phase 3 Unknown